Pharm-Sintez — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

AO Pharm-Sintez is a leading Russian generic drug manufacturer, strategically positioned within the state-subsidized pharmaceutical provision system. The company leverages vertical integration, controlling the production process from active ingredient synthesis to finished dosage forms, which provides cost and supply chain advantages. Its product portfolio targets several key therapeutic areas including gynecology, surgery, neurology, oncology, endocrinology, and urology. While financial details are limited, the company reported sales exceeding 1.85 billion rubles in 2015 and is engaged in a significant plant construction project to expand capacity.

GynecologySurgeryNeurologyOncologyEndocrinologyTheranosticsUrology

Technology Platform

Vertically integrated generic drug manufacturing platform, encompassing active pharmaceutical ingredient (API) development/synthesis and finished dosage form production.

Opportunities

The company is well-positioned to benefit from Russian government policies favoring domestic pharmaceutical production and import substitution, particularly within the large, state-subsidized drug provision program.

Expansion of manufacturing capacity through a new plant construction project could enable increased market share and potential export opportunities to CIS countries.

Risk Factors

High dependence on the Russian state procurement system creates regulatory and customer concentration risk.

The broader geopolitical environment and international sanctions pose significant supply chain and operational challenges.

The generics market is also subject to intense price competition and margin pressure.

Competitive Landscape

Pharm-Sintez competes in the crowded Russian generics market against other domestic manufacturers like Pharmstandard, Obolenskoe, and Veropharm, as well as multinational generics companies with local production. Its key competitive differentiator is its vertical integration, controlling API synthesis, which provides cost and supply security advantages in a market prioritizing localization.

More companies in Europe - Other →